Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sol-Gel Technologies Ltd. (NASDAQ: SLGL).

Full DD Report for SLGL

You must become a subscriber to view this report.


Recent News from (NASDAQ: SLGL)

Sol-Gel Technologies Announces Participation in Upcoming Investor Conference
NESS ZIONA, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...
Source: GlobeNewswire
Date: November, 05 2018 16:05
Sol-Gel Technologies Announces an Additional Collaborative Agreement for a Generic Product Candidate with Perrigo
NESS ZIONA, Israel, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...
Source: GlobeNewswire
Date: November, 01 2018 16:05
Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay® Program for the Treatment of Papulopustular Rosacea
Patient enrollment of the pivotal Phase III Epsolay clinical trials is on schedule Top-line results expected in 2019 NESS ZIONA, Israel, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-...
Source: GlobeNewswire
Date: September, 25 2018 16:05
Sol-Gel Technologies Provides Program Update for TWIN for the Treatment of Acne Vulgaris
Announces Positive End-of-Phase II Meeting with the FDA Receives Special Protocol Assessment (SPA) Agreement from FDA Company expects to commence the TWIN Phase III clinical trials in the fourth quarter of 2018 with top-line data expected in 2019 NESS ZIONA, Israel, Sept. 04, 2...
Source: GlobeNewswire
Date: September, 04 2018 16:05
Sol-Gel Technologies Announces Collaborative Agreement for Generic Product with Perrigo
NESS ZIONA, Israel, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...
Source: GlobeNewswire
Date: August, 15 2018 16:05
Sol-Gel Technologies Reports Second Quarter 2018 Financial Results
NESS ZIONA, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...
Source: GlobeNewswire
Date: August, 08 2018 07:05
Stocks To Watch: Apple, Harley And Tesla On The Marquee
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Will Apple (AAPL) percolate right along after earnings unlike the tracks of Faceboo...
Source: SeekingAlpha
Date: July, 28 2018 08:27
Your Daily Pharma Scoop: TG Therapeutics Phase 2 Results, Geron Positive, Agio In Phase 3
Analysis Focus: TGTX TG Therapeutics ( TGTX ) announced preliminary data from the Phase 2 clinical trial of its lead candidate umbralisib (TGR-1202) in patients with relapsed/refractory chronic lymphocytic leukemia or r/r CLL, who were intolerant to prior BTK or PI3K therapy. The data that...
Source: SeekingAlpha
Date: June, 20 2018 08:00
Sol-Gel launches late-stage development of Epsolay for rosacea
Sol-Gel Technologies (NASDAQ: SLGL ) commences pivotal Phase 3 development of topical cream Epsolay (formerly VERED) in patients with papulopustular rosacea, an inflammatory condition typically appearing on the face. More news on: Sol-Gel Technologies Ltd., Healthcare stocks news, Re...
Source: SeekingAlpha
Date: June, 18 2018 16:53
Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program for Papulopustular Rosacea
First subject dosed in pivotal Phase III program evaluating Epsolay ® in subjects with papulopustular rosacea Two Phase III trials expected to enroll a total of 700 subjects Top-line data expected to be reported in 2019 NESS ZIONA, Israel, June 18, 2018 (GLOBE NEWSWI...
Source: GlobeNewswire
Date: June, 18 2018 16:33

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-087.757.477.79957.07122,683
2018-05-178.859.509.68998.858,108

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-104002,55615.6495Cover
2018-12-071,1503,30034.8485Cover
2018-12-061,2532,25355.6147Short
2018-12-042321,97911.7231Cover
2018-12-032,4283,00380.8525Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SLGL.


About Sol-Gel Technologies Ltd. (NASDAQ: SLGL)

Logo for Sol-Gel Technologies Ltd. (NASDAQ: SLGL)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: SLGL)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 15 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 17 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 26 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 26 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 22 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 26 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 26 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 15 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 12 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: February, 12 2018

       

       


      Daily Technical Chart for (NASDAQ: SLGL)

      Daily Technical Chart for (NASDAQ: SLGL)


      Stay tuned for daily updates and more on (NASDAQ: SLGL)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: SLGL)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SLGL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SLGL and does not buy, sell, or trade any shares of SLGL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/